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Introduction:
Breast cancer affects more than 200,000 women each year in the United States (1), and most women diagnosed at an early stage have potentially curable disease. The 5-year survival rate for those diagnosed with localized breast cancer has increased from 80% in the 1950's to 98% in 2000 (2) . Between 1990 and 2000, the mortality rate from breast cancer decreased by 2.3% annually. Decreases were most impressive in women under age 50, for whom mortality rates decreased by 3.7%.
Owing to the improved survival associated with administration of adjuvant chemotherapy and/or radiation therapy, the majority of women diagnosed with breast cancer will receive some type of adjuvant treatment (3). Impairment in neurocognitive function can accompany chemotherapy with deficits including memory loss, difficulty with concentration, difficulty learning new material, reading comprehension, distractibility, difficulty in performing multiple tasks (multi-tasking), altered visual/spatial orientation, verbal fluency, and the ability to work with numbers (4). Adult cancer survivors also report persistent changes in cognitive function following chemotherapy (5). The President 's Cancer Panel (1999) identified cognitive deficits associated with cancer treatment as having a dramatic negative impact on quality of life; the Panel cited cognitive deficits and quality of life as problems that should be addressed both clinically and in the research arena.
Research on the impact of chemotherapy on cognitive function can be traced to the early 1980's. This research produced mixed results regarding the impact of therapy on the development of cognitive deficits (6-9). More recently, studies have revealed relationships among cognitive deficits, chemotherapy receipt, and diminished quality of life. However, questions remain regarding the neurotoxic impact of chemotherapy: Are the problems acute or chronic? Does the type and duration of therapy make a difference? How does chemotherapy affect the central nervous system? Does undergoing an accelerated menopause and change in the hormonal milieu associated with chemotherapy relate to cognitive change? Do other psychological factors influence the extent of cognitive decline? Does the stage of disease influence the severity or duration of symptoms? The proposed research will attempt to address some of these unanswered questions, specifically focusing on evaluating change in cognitive function and quality of life associated with cancer treatment in a sample of young breast cancer patients receiving a relatively uniform treatment regimen.
Body:
This is a hypothesis generating pilot study to explore multiple variables including cognitive function and quality of life in response to receiving adjuvant or neoadjuvant chemotherapy every two or three weeks for the treatment of breast cancer. Approximately sixty pre and peri-menopausal women with breast cancer receiving adjuvant or neoadjuvant chemotherapy every 2 to 3 weeks will be recruited to participate in this pilot study. Women will undergo a battery of psychosocial tools and have serum estradiol, FHS levels and hemoglobin values assessed. The battery of psychosocial tools and serum values will be collected at baseline, prior to the third cycle of chemotherapy, and approximately three to four weeks following completion of chemotherapy but prior to any antihormonal or radiation therapy. The battery of psychosocial tools will include measurements of cognition by the Cognitive Difficulities Scale and High Sensitivity Cognitive Screen; quality of life measured by the MOS-SF-36 and the BCPT Symptom Checklist; fatigue will measured by the FACT-An and the Brief Fatigue Inventory; Depression and Coping will be measured by the Beck Depression Index and the Brief COPE; and Hope, Optimism and Pessimism will be measured by the Hope scale, the LOT-R, and the PANAS.
• Hypothesis:
We predict that young women with breast cancer receiving chemotherapy will experience decrements in cognitive function and quality of life, and increases in menopausal symptoms and fatigue over the course of treatment. We also predict that deficits in cognitive function, and an increase in treatment-related symptoms and fatigue, may be associated with accelerated menopause (i.e., decline in estradiol).
• To analyze these data we will use repeated measures analysis of variance, with Time as a threelevel factor, to examine pre-mid-post changes in cognitive function using the Cognitive Difficulties Scale and the HSCS scales. Repeated measures analysis also will be used to assess changes in serum estradiol levels, serum hemoglobin levels, fatigue, menopausal symptoms, depressive symptoms, and quality of life measures. Follow-up paired t-tests will be conducted to determine the locus of significant effects (i.e., Time 1 to Time 2, Time 2 to Time 3, Time 1 to Time 3).
We also will evaluate the relationship between change in cognitive function (i.e., HSCS, Cognitive Difficulties Scale) and change in the following individual variables: serum estradiol levels, symptoms of fatigue, serum hemoglobin level, depressive symptoms, menopausal symptoms, and measures of quality of life. We will examine correlations of change scores (e.g., change in estradiol from Time 1 to Time 2 correlated with change in a cognitive function variable from Time 1 to Time 2), although it can be difficult to specify the source of variability accounting for the obtained relationship in correlated change scores. We also will examine partial correlations (e.g., Time 3 cognitive function correlated with Time 2 estradiol, partialling out Time 2 cognitive function). If multiple variables are found to predict change in cognitive function, we will conduct exploratory multiple regression analyses (e.g., cognitive function at Time 3 regressed on Time 2 cognitive function, estradiol, and fatigue). In these analyses, we will pay greater attention to proportion of variance accounted for by each predictor than to significance level, in light of the small sample size.
Key Accomplishments:
• Revised protocol was accepted by the Human Subjects Committee in April 2005.
• 
Conclusions:
These results suggest that young women with breast cancer receiving chemotherapy perceive a significant impairment in cognitive function, but do not show significant impairment on a standardized measure, while experiencing a significant decrease in serum hormones, increase in depressive symptoms, and an overall decrease in QofL. A better understanding of the association between chemotherapy and QofL is essential to provide appropriate preventive approaches and interventions aimed at maximizing the QofL and health of young women with breast cancer. Body: Background: Significant reductions in quality of life (QofL) and cognitive function are experienced by women with breast cancer receiving chemotherapy. The majority of relevant research has been based on retrospective data. Current estimates suggest that 25% of breast cancers will be diagnosed in women under age 50, and little data are available regarding younger women s cognitive function and QofL during chemotherapy. The purpose of this pilot study was to evaluate the effects of accelerated menopause on measures of cognitive function, quality of life variables, and symptoms of depression in pre-menopausal women with a new diagnosis of breast cancer being treated with adjuvant or neo-adjuvant chemotherapy.
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Methods:
The goal of this study is to examine change in cognitive function and QofL in 20 pre-menopausal women with breast cancer receiving chemotherapy. To determine if accelerated menopause is associated with change in cognition and quality of life, serum hormone levels (E2, FSH) measures of cognitive function (High Sensitivity Cognitive Screen (HSCS), Cognitive Difficulties Scale, perception of function), quality of life variables (Breast Cancer Prevention Trials Symptom Check list, MOS-SF-36), and symptoms of depression (Beck Depression Inventory) were assessed. Measures were collected at baseline (before the initiation of chemotherapy), prior to the third cycle of chemotherapy, and following completion of chemotherapy, but prior to any additional treatment. A repeated measures analysis was used to assess changes in serum estradiol levels, serum hemoglobin levels, fatigue, depressive symptoms, and QofL measures.
Results:
The median age of the pre-menopausal women with breast cancer was 43 and 70% had at least a college degree. Eightyseven percent of subjects received dose-dense chemotherapy with an anthracycline cyclophosphomide regimen and 50% received neo-adjuvant chemotherapy. E2 levels were significantly (p=.018, Wilcoxon Signed Ranks test) decreased from a median pretreatment estradiol level of 67.7 pg/ml [range, 37.4-106] to a median post-treatment level of 30.5 pg/ml [range, 14.7-57.6 ]. Women reported an increase in symptoms associated with QofL and depression. Women also reported an increased perception of impairment within concentration and memory domains, even though this was not reflected in changes in memory HSCS subtest scores.
Conclusion:
These results suggest that young women with breast cancer receiving chemotherapy perceive a significant impairment in cognitive function, but do not show significant impairment on a standardized measure, while experiencing a significant decrease in serum hormones, increase in depressive symptoms, and an overall decrease in QofL. A better understanding of the association between chemotherapy and QofL is essential to provide appropriate preventive approaches and interventions aimed at maximizing the QofL and health of young women with breast cancer.
Results
Sample Characteristics and Study Recruitment
As depicted in Table 2 , participants were 20 pre-menopausal women with a recent diagnosis of breast cancer, who had not yet received chemotherapy at study entry, but had undergone a biopsy and/or definitive surgery and their planned treatment included chemotherapy (Adrimycin & Cytoxan,
Epirubicin & Cytoxan, Herceptin or Carboplatinum + Taxotere). Thirty women were invited to participate in the study and were provided with a written overview of the clinical trial. Twenty women agreed to participate, signed an informed consent, began and completed the study, and their results are presented in this analysis. Reasons why some women opted not to participate in the study included timing of their initial treatment (e.g. started treatment the same day as their clinic visit) or travel distance to and from the cancer center. The median age of the study population was 43 years old ( range 28-51), the majority of the subjects were white (85%), 80% of the subjects had at least a college education, and 85% were working full or part-time.
Effects on Cognitive Functioning
Repeated measures analyses of variance revealed no significant effect of treatment on objective cognitive functioning measured by the HSCS (Table 3) . However, the memory subscale of the HSCS demonstrated a significant improvement in memory between baseline and post-treatment assessments p=.042. The subjective measure of cognitive functioning, the CDS, also did not demonstrate a significant decline in cognitive functioning (F (1,19) = 1.07, p=.31).
By clinical interview at the off-study visit, subjects reported difficulty with word finding, memory, and speed of processing. Subjective changes in cognitive functioning also emerged from the BCPT Cognitive Problems scale, (F (1,19) = 8.44, p= 0.009).
Change in Serum Hormones Levels and Menopause Status
Only three subjects reported having a single menstrual period following the initiation of their chemotherapy regimen. All others stopped menstruating. Repeated measures analysis of variance revealed changes in serum hormones and hemoglobin levels over the course of treatment (Table 4 ).
Significant decreases in estradiol and hemoglobin levels were detected. Non-significant increases were noted in testosterone and progesterone levels, and IGF1/IGFBP-3 ratios remained consistent. 
Quality of Life Variables
Depressive symptoms: Repeated analyses of variance detected a significant increase in depressive symptoms (Table 5 ) on the BDI (F (1,19) = 14.2, p <.001 ) over the course of treatment. Mean group BDI scores at baseline and mid-treatment were not elevated to the cutoff of 10, which is suggestive of mild clinical depression, but the post-treatment mean was over the threshold. However, 20% of subjects at baseline, 35% of subjects mid-treatment, and 55% of post-treatment subjects had a BDI score of at least 10, indicating that number of subjects had symptoms suggestive of at least mild clinical depression (Table 6) . By treatment completion, 45% reported negligible symptoms and 55%
reported at least mild symptoms of depression. In contrast, a non-significant increase in depressive symptoms (Tables 5 and 6 ) was observed on the CES-D. Mean CES-D levels were not elevated over the course of treatment, but 30% of subjects at baseline, 20% of subjects mid-treatment, and 50% of subjects post-treatment had a CES-D score of at least 16 (Radloff, 1977) , the cutoff suggestive of clinical depression.
Health related quality of life: the SF-36 and the FACT were use to assess psychological functioning.
Lower scores on the SF-36 reflect poorer quality of life. Table 7 provide normative data on the SF-36 subscales broken down by age (Ware, 1993 (Ware, , 1994 . Repeated within subjects analysis of variance using the SF-36 Emotional Function scale (F(1,19)= .137, p=.716) and the SF-36 Mental Health scale (F(1,19) = .085, p=.774) did not find significant differences over the course of treatment (Table 8) .
Repeated analyses of variance revealed a significant negative impact on physical functioning as reported by the SF-36 Physical Functioning Scale (F (1,19) = 4.91, p <.039). Other SF-36 measures of General Health and Social Functioning, did not demonstrate a significant difference over the course of treatment. The mean baseline Mental Health summary score (Table 7) was similar to those seen by other studies of women with early-stage breast cancer (Burstein, Gelber, Guadagnoli, & Weeks, 2007 ) and compared to a normative data set (Ware, 1993 (Ware, , 1994 Table 4 Within-Subjects Change in serum hormone levels over the course of treatment
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